Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan.
暂无分享,去创建一个
F. Fedele | M. Mancone | C. Vizza | C. Letizia | V. Riccieri | R. Badagliacca | S. Papa | B. Pezzuto | R. Poscia | C. Iacoboni | C. Gambardella | S. Marcon | M. Volterrani | Alfred Nona
[1] A. Coats,et al. Ethics in the authorship and publishing of scientific articles , 2010 .
[2] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[3] M. Bolli,et al. Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist , 2008, Journal of Pharmacology and Experimental Therapeutics.
[4] F. Fedele,et al. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension , 2008, Regulatory Peptides.
[5] T. Fleming,et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. , 2008, Chest.
[6] A. Coca,et al. Aldosterone Escape With Diuretic or Angiotensin‐Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Combination Therapy in Patients With Mild to Moderate Hypertension , 2007, Journal of clinical hypertension.
[7] M. Humbert,et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. , 2007, Chest.
[8] A. Torbicki,et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.
[9] M. Humbert,et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. , 2006, European heart journal.
[10] T. Welte,et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension , 2005, European Respiratory Journal.
[11] R. Barst,et al. Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.
[12] F. Fedele,et al. Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease , 2005, Regulatory Peptides.
[13] J. Dingemanse,et al. Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist , 2004, Clinical pharmacokinetics.
[14] Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.
[15] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[16] K. Kangawa,et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.
[17] C. Letizia,et al. Plasma endothelin-1 levels in normotensive and borderline hypertensive subjects during a standard cold pressor test. , 1995, Journal of human hypertension.
[18] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[19] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.